Cannabis Report
Home > Boards > US OTC > Biotechs > CYTODYN INC (CYDY)

My opinion on what happened is that there

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
gestalt2 Member Profile
 
Followed By 5
Posts 782
Boards Moderated 1
Alias Born 04/13/16
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/15/2018 7:49:45 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2018 7:44:52 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 6:04:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 6:03:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:59:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:59:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:57:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:56:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:56:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:55:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:54:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/7/2018 4:24:25 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/22/2018 8:16:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/22/2018 7:46:52 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/22/2018 7:45:17 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/8/2018 4:06:32 PM
Proxy Soliciting Materials (revised) (prer14a) Edgar (US Regulatory) - 5/4/2018 10:54:38 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/26/2018 5:09:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/11/2018 6:09:06 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/9/2018 4:34:49 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) Edgar (US Regulatory) - 3/26/2018 5:27:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/26/2018 5:25:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/26/2018 8:02:44 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 3/26/2018 6:02:12 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 3/23/2018 4:28:34 PM
gestalt2   Friday, 11/10/17 06:45:00 PM
Re: BlackDoggie post# 18100
Post # of 23442 
My opinion on what happened is that there seemed to be some confusion between cytodyn and the FDA, the FDA wanted a face to face to resolve something. I feel that cytodyn is asking or expecting a wider label and thought they would get it. the FDA lowered the enrollment to 30 because tai med was allowed to have that trial size but they were looking at a much narrower label. The fact that cytodyn did not really elaborate on why this happened or what the specifics of the discussion suggests there was some sort of misunderstanding that Nader should have been on top of. It could be the 50patients and 300 safety data solves this and ensures a broad label. It could very well be that the FDA could have stuck with the original 150 trial size if at that time cytodyn was asking for a broad label. Either way, I think it is safe to assume Nader was a little loose with the details of the combo trial.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist